Advertisement
Advertisement
GSK
GSK plc - ADR
47.03
USDSponsored
-0.15
-0.32%
Oct 02, 15:59 UTC -4
Closed
After-Market
47.02
-0.01
-0.02%
GSK Earnings Reports
Positive Surprise Ratio
GSK beat 35 of 42 last estimates.
83%
Next Report
Date of Next Report
Oct 28, 2026
Estimate for Q3 26 (Revenue/ EPS)
$9.16B
/$0.53
Implied change from Q2 26 (Revenue/ EPS)
+8.92%
/+6.00%
Implied change from Q3 25 (Revenue/ EPS)
+7.16%
/-3.64%
GSK plc - ADR earnings per share and revenue
On Jul 28, 2026, GSK reported earnings of 0.50 USD per share (EPS) for Q2 26, beating the estimate of 0.47 USD, resulting in a 6.65% surprise. Revenue reached 8.41 billion, compared to an expected 8.49 billion, with a -0.91% difference. The market reacted with a +3.33% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 5 analysts forecast an EPS of 0.53 USD, with revenue projected to reach 9.16 billion USD, implying an increase of 6.00% EPS, and increase of 8.92% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
Nanobiotix S.A. - ADR
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.70
Surprise
-496.76%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$0.07
Surprise
+2,158.06%
Inventiva S.A. - ADR
Report Date
Sep 28, 2026 For Q2 26
Estimate
-$0.37
Actual
-$0.25
Surprise
+33.55%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Rezolute, Inc. Common Stock (NV)
Report Date
Sep 24, 2026 For Q4 26
Estimate
-$0.15
Actual
-$0.20
Surprise
-32.45%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
$0.00
Surprise
+99.70%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Palatin Technologies, Inc. Common Stock
Report Date
Sep 28, 2026 For Q4 26
Estimate
-$1.21
Actual
-$1.11
Surprise
+8.42%
FAQ
What were GSK plc - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, GSK plc - ADR reported EPS of $0.50, beating estimates by 6.65%, and revenue of $8.41B, -0.91% below expectations.
How did the market react to GSK plc - ADR's Q2 2026 earnings?
The stock price moved up 3.33%, changed from $51.98 before the earnings release to $53.71 the day after.
When is GSK plc - ADR expected to report next?
The next earning report is scheduled for Oct 28, 2026.
What are the forecasts for GSK plc - ADR's next earnings report?
Based on 5
analysts, GSK plc - ADR is expected to report EPS of $0.53 and revenue of $9.16B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.